Rothschild Investment LLC’s Corvus Pharmaceuticals CRVS Stock Holding History

Rothschild Investment LLC’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$105K	Sell	7,052 -448	-6%	-$6.22K	﹤0.01%	1039
2026 Q1	$110K	Buy	7,500 +500	+7%	+$7.98K	0.01%	854
2025 Q4	$53.9K	Hold	7,000	–	–	﹤0.01%	998
2025 Q3	$51.6K	Hold	7,000	–	–	﹤0.01%	978
2025 Q2	$28K	Hold	7,000	–	–	﹤0.01%	939
2025 Q1	$22.3K	Hold	7,000	–	–	﹤0.01%	976
2024 Q4	$37.5K	Hold	7,000	–	–	﹤0.01%	850
2024 Q3	$37K	Hold	7,000	–	–	﹤0.01%	852
2024 Q2	$12.7K	Hold	7,000	–	–	﹤0.01%	1070
2024 Q1	$12.5K	Buy	+7,000	New	+$14.6K	﹤0.01%	1024

Other funds holding CRVS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Rothschild Investment LLC's CRVS Position: Q2 2026 in Review

Rothschild Investment LLC reduced its Corvus Pharmaceuticals (CRVS) stake by 6% in Q2 2026, selling an estimated $6.22K and leaving 7,052 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #1039.

Rothschild Investment LLC first reported a position in CRVS in Q1 2024 and has held it in 10 quarters since. The position peaked at $110K in Q1 2026. 114 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

Rothschild Investment LLC held 7,052 shares of Corvus Pharmaceuticals worth $105K as of Q2 2026.
Rothschild Investment LLC sold 448 Corvus Pharmaceuticals shares in Q2 2026, an estimated $6.22K.
Corvus Pharmaceuticals made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #1039 holding.
Rothschild Investment LLC first reported a position in Corvus Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Rothschild Investment LLC's Corvus Pharmaceuticals position peaked at $110K in Q1 2026.
114 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.